-- 根據FactSet調查的分析師報告，YETI Holdings (YETI) 的平均評級為“增持”，平均目標價為50.47美元。 （報道北美、亞洲和歐洲主要銀行及研究機構的股票、商品和經濟研究。研究機構可透過以下連結聯絡我們：https://www..com/contact-us）
Price: $41.77, Change: $-0.69, Percent Change: -1.63%
Related Articles
Sectors
Sector Update: Financial
Financial stocks fell in Thursday afternoon trading with the NYSE Financial Index and the State Street Financial Select Sector SPDR ETF (XLF) each shedding 0.5%.The Philadelphia Housing Index dropped 1.1%, and the State Street Real Estate Select Sector SPDR ETF (XLRE) declined 0.5%.Bitcoin (BTC-USD) fell 2% to $79,831, and the yield for 10-year US Treasuries rose 2.2 basis points to 4.378%.In corporate news, JPMorgan Chase (JPM) and Citigroup (C) were sued by China's HY Energy over alleged failure of funds transfer, Bloomberg reported. JPMorgan shares fell 2%, and Citi rose 1.8%.
$C$JPM
Research
Research Alert: CFRA Lowers Rating On Shares Of Bio-techne Corporation To Sell From Hold
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our 12-month target is $44, down from $59, 21.2x our FY 27 EPS estimate. Our multiple is below TECH's one-year historical forward average of 26.1x and the three-year average of 30.7x. We lower our FY 26 EPS estimate by $0.06 to $1.92 and our FY 27 estimate by $0.09 to $2.08. Along with peers, shares have been under pressure due to concerns around NIH and U.S. academic research funding, an important end market for the company, as well as a slowly recovering biotech funding environment. Though we see some indications of improving conditions, we prefer some of TECH's larger, more diversified peers over the near term and think shares are more likely to underperform despite expected sales/EPS growth. We note multiple recent quarters of growth for the large pharma end market and China/APAC sales. Similar to recent commentary from life sciences tools and services peers, TECH sees indications of improving biotech funding, as well as licensing and M&A activity, heading into FY 27.
$TECH
Sectors
Sector Update: Health Care
Health care stocks declined Thursday afternoon with the NYSE Health Care Index shedding 0.9% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.7%.The iShares Biotechnology ETF (IBB) dropped 2.9%.In corporate news, Iovance Biotherapeutics (IOVA) shares fell 14% after the company's Q1 loss narrowed less than expected and revenue missed estimates.
$IOVA